Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.57 |
| ▸ | DRD2 | P14416 | 3/20 | 0.57 |
| ▸ | DRD3 | P35462 | 3/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 3/20 | 0.52 |
| ▸ | HTR2C | P28335 | 3/20 | 0.52 |
| ▸ | HRH1 | P35367 | 2/20 | 0.52 |
| ▸ | HRH2 | P25021 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 3/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3594803 | 0.87 | HRH3 (0.51) | SIGMAR1KCNH2HRH1HRH3KDM4E | |
| SCHEMBL3604671 | 0.86 | SLC2A2 (0.55) | SIGMAR1CYP2D6KDM4EGAA | |
| SCHEMBL3597755 | 0.85 | HRH3 (0.52) | SIGMAR1KCNH2HRH1HRH3KDM4E | |
| SCHEMBL3602354 | 0.83 | HRH3 (0.55) | KCNH2HRH1HRH3 | |
| SCHEMBL3599589 | 0.82 | HRH3 (0.56) | KCNH2HRH1HRH3 | |
| SCHEMBL3600202 | 0.80 | MEN1 (0.54) | HTR1ASIGMAR1DRD2DRD3HTR2A | |
| SCHEMBL3605027 | 0.79 | SLC2A2 (0.58) | CYP2D6KDM4EGAA | |
| SCHEMBL3599212 | 0.77 | CYP1A2 (0.54) | HTR1ASIGMAR1DRD3KCNH2SLC6A2 | |
| SCHEMBL18754269 | 0.77 | KDM4E (0.75) | HTR1ASIGMAR1DRD2DRD3HTR2A | |
| SCHEMBL5988317 | 0.77 | KCNH2 (0.88) | HTR1ASIGMAR1DRD2DRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097392-B1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2013-03-13 | — | — | EP | claimed |
| US-8193223-B2 | 1,2,3-triazole derivatives as sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-05 | — | — | US | claimed |
| US-20100004265-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. | 2010-01-07 | — | — | US | claimed |
| EP-2097392-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-09-09 | — | — | EP | claimed |
| WO-2008055933-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-05-15 | — | — | WO | claimed |
| EP-1921071-A1 | 1,2,3- triazole derivatives as sigma receptor inhibitors | Laboratorios del Dr. Esteve S.A. (ES) | 2008-05-14 | — | — | EP | claimed |
| EP-2097392-B1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2013-03-13 | — | — | EP | disclosed |
| US-8193223-B2 | 1,2,3-triazole derivatives as sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-05 | — | — | US | disclosed |
| US-20100004265-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. | 2010-01-07 | — | — | US | disclosed |
| EP-2097392-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008055933-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-05-15 | — | — | WO | disclosed |
| EP-1921071-A1 | 1,2,3- triazole derivatives as sigma receptor inhibitors | Laboratorios del Dr. Esteve S.A. (ES) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004265-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | SIGMAR1, OPRK1, OPRD1 | HTR1A 19/4885SIGMAR1 1/4885DRD2 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.